Alzheimer's disease is caused by damage to nerve cells in the brain. One way this damage can occur is through the buildup of a substance called amyloid beta. This buildup interferes with communication between nerve cells and leads to cell death.
We're testing two investigational study medications against placebo in this study to see if they may protect the brain from this buildup. In other words, we are trying to learn how effectively two drugs prevent or delay the onset of Alzheimer's disease symptoms. These study medications are called "investigational" because they are being studied, but are not currently approved by the FDA or available for use by the public.
In the Generation Study, we're providing the chance to try one of these investigational study medications or placebo— at no cost — to people whose genetic information shows they have a high risk of developing Alzheimer's.
If you're interested in being considered for this study, please take the first step in our 3-step process — take our simple, no-commitment questionnaire to see if you are eligible.Let's Go!
Along with participation from people like you, this study brings together some of the best and brightest organizations in the Alzheimer's community:
The study is sponsored by Novartis, a Swiss pharmaceutical company, and Amgen, a biotechnology company based in Thousand Oaks, CA, in collaboration with BAI, with funding from the National Institute on Aging, part of the National Institutes of Health (NIH), as well as the Alzheimer’s Association, FBRI, GHR Foundation and Banner Alzheimer’s Foundation.